Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Kiromic BioPharma, Inc.
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
August 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
August 09, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
August 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
July 18, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
June 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
June 06, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
May 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
OTC
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
May 01, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
April 03, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces Reverse Stock Split
March 10, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
February 28, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
February 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma CEO Issues Letter to Stockholders
February 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Arranges Up to $10 Million Financing
October 27, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
October 06, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
July 12, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Tickers
KRBP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.